Alberta Site Currently Recruiting for ViaCyte Inc. Clinical Trial

The highly anticipated encapsulation trial is looking for participants 

Toronto, Ontario – December 17, 2015, The University of Alberta is currently recruiting for the highly anticipated STEP ONE (Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type One Diabetes) encapsulation trial located in Edmonton, Canada. The company that is sponsoring the trial, ViaCyte, announced in July that it would open the second site to investigate the VC-01 combination product trial in Alberta alongside JDRF-funded researcher Dr. James Shapiro and his world-renowned team.

The purpose of this research is to assess the safety, tolerability, and effectiveness of a new delivery system as well as replacement pancreatic cells. Participants may be eligible for this study if they are an adult (between the ages of 18 and 55 years old), have been diagnosed with type 1 diabetes (T1D) for a minimum of three years, and have a stable, optimized diabetic regimen for at least three months.   Because the study requires many visits to the clinic, Canadian subjects living in the Edmonton area would be most likely to successfully participate. For the complete information package, please visit

If you are interested in learning more about the study, please call 780-407-7739 or 780-407-1480. You can also email Dr. Andrew Malcolm (Operations Director – Clinical Trials) [email protected] for more information.

About JDRF Canada

JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF’s goal is to progressively remove the impact of T1D from people’s lives until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D. JDRF is the largest charitable supporter of T1D research. For more information, please visit

About ViaCyte Inc.

ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes. ViaCyte is conducting a Phase 1/2 clinical trial of the Company’s lead
VC-01™ product candidate in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. ViaCyte’s VC-01™ combination product is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells. These progenitor cells are implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. The VC-01™ product is being developed as a potential long-term diabetes treatment without immune suppression, and without risk of hypoglycemia or other diabetes-related complications. ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF. 

JDRF Media Contact

Julie Andaloro

National Manager, Communications and Public Relations

[email protected]


Lets turn type one into type none